- Home
- PSFE vs PHAT Comparison
PSFE vs PHAT Comparison
Compare PSFE & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PSFE
- PHAT
- Stock Information
- Founded
- PSFE 1996
- PHAT 2018
- Country
- PSFE United Kingdom
- PHAT United States
- Employees
- PSFE N/A
- PHAT N/A
- Industry
- PSFE Business Services
- PHAT Biotechnology: Pharmaceutical Preparations
- Sector
- PSFE Consumer Discretionary
- PHAT Health Care
- Exchange
- PSFE Nasdaq
- PHAT Nasdaq
- Market Cap
- PSFE 1.4B
- PHAT 1.2B
- IPO Year
- PSFE N/A
- PHAT 2019
- Fundamental
- Price
- PSFE $17.50
- PHAT $9.45
- Analyst Decision
- PSFE Hold
- PHAT Strong Buy
- Analyst Count
- PSFE 6
- PHAT 4
- Target Price
- PSFE $19.40
- PHAT $22.50
- AVG Volume (30 Days)
- PSFE 467.1K
- PHAT 1.9M
- Earning Date
- PSFE 11-13-2024
- PHAT 11-07-2024
- Dividend Yield
- PSFE N/A
- PHAT N/A
- EPS Growth
- PSFE N/A
- PHAT N/A
- EPS
- PSFE N/A
- PHAT N/A
- Revenue
- PSFE $1,699,306,000.00
- PHAT $26,270,000.00
- Revenue This Year
- PSFE $9.80
- PHAT $6,714.96
- Revenue Next Year
- PSFE $7.00
- PHAT $293.69
- P/E Ratio
- PSFE N/A
- PHAT N/A
- Revenue Growth
- PSFE 8.22
- PHAT N/A
- 52 Week Low
- PSFE $10.05
- PHAT $6.07
- 52 Week High
- PSFE $26.25
- PHAT $19.71
- Technical
- Relative Strength Index (RSI)
- PSFE 34.23
- PHAT 30.83
- Support Level
- PSFE $16.67
- PHAT $8.55
- Resistance Level
- PSFE $26.25
- PHAT $19.05
- Average True Range (ATR)
- PSFE 1.01
- PHAT 1.68
- MACD
- PSFE -0.63
- PHAT -0.65
- Stochastic Oscillator
- PSFE 8.66
- PHAT 8.68
About PSFE Paysafe Limited
Paysafe Ltd is an integrated payments platform. Its core purpose is to enable businesses and consumers to connect and transact seamlessly through capabilities in payment processing, digital wallet, and online cash solutions. The company provides payment solutions through three primary lines of business: Integrated Processing, Digital Wallet, and eCash Solutions. It derives a majority of revenue from the USA followed by Germany, the UK, and all other countries.
About PHAT Phathom Pharmaceuticals Inc.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.